The Ohio State University Wexner Medical Center James Cancer Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sardesai, Sagar
BRCA-P, NCT04711109 / 2017-002505-35: Studying the Effect of Denosumab on Preventing Breast Cancer in Women with a BRCA1 Germline Mutation

Active, not recruiting
3
300
US
Denosumab, Placebo, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Austrian Breast & Colorectal Cancer Study Group (ABCSG)
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
07/27
12/33
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
NCT06195306: Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Not yet recruiting
2
66
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Mammography, MG, Omega-3-Acid Ethyl Esters, Lovaza, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Random Periareolar Fine Needle Aspiration, RPFNA, Tamoxifen, TMX
National Cancer Institute (NCI)
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
01/27
01/27
TIFA, NCT05090358: Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Active, not recruiting
2
15
US
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Piqray, Fulvestrant, Faslodex, Canagliflozin, Invokana
Memorial Sloan Kettering Cancer Center
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
10/25
10/25
NCT05941520: Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Recruiting
2
80
US
Acolbifene Hydrochloride, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Mammography, MG, Random Periareolar Fine-Needle Aspiration, Random Periareolar Fine Needle Aspiration, RPFNA, Tamoxifen, TMX
National Cancer Institute (NCI)
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
08/27
09/28
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT05751668: Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment with Paclitaxel (Phase II)

Recruiting
2
98
US
Paclitaxel, Anzatax, Asotax, Bristaxol, Monosialotetrahexosylganglioside, Ganglioside GM-1, GM-1, GM1, Monosialoanglioside GM1, Questionnaire Administration, Quality-of-life assessment, Placebo Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC V8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
01/26
05/30
NCT02204098: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Active, not recruiting
1
27
US
Mammaglobin-A DNA Vaccine, Optional biopsy
Washington University School of Medicine, Rising Tide Foundation, United States Department of Defense
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
04/22
08/28
CX-5461-04, NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting
1
52
Canada, US
CX-5461, Pidnarulex
Senhwa Biosciences, Inc.
Advanced Solid Tumor
12/24
06/25
NCT05086705: EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Active, not recruiting
N/A
50
US
EMBr Wave, Questionnaire Administration
Ohio State University Comprehensive Cancer Center, Embr Labs, Inc.
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Hot Flashes
08/23
12/24
NCT05012176: An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors

Completed
N/A
50
US
Behavioral Intervention, Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Ohio State University Comprehensive Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
11/23
11/23
NCI-2021-03342, NCT05178498: Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Recruiting
N/A
960
US
Follow-Up, Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow Up, follow_up, Followed, Followup, Physical Examination, Assessment, General Examination, Physical, Physical Assessment, Physical Exam, physical_exam, Questionnaire Administration
Ohio State University Comprehensive Cancer Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
12/35
12/35
IMOCS, NCT05193149: Inspiratory Muscle Training in Obese Breast Cancer Survivors

Recruiting
N/A
78
US
Inspiratory muscle training, Exercise training
Ohio State University Comprehensive Cancer Center
Cancer Survivors, Obesity, Breast Cancer
06/28
06/29
Giali, Raoof
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996, Nanatinostat, Valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
Shindiapina, Polina
NCT02532452: Third Party Viral Specific T-cells (VSTs)

Recruiting
2
750
US
Viral Specific VST Infusion
Children's Hospital Medical Center, Cincinnati
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
12/26
12/27
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Active, not recruiting
1/2
22
US
Infusion of NEXI-001 T Cells
NexImmune Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
10/24
03/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996, Nanatinostat, Valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
Trumbull, Ashley
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
NCT06492759: High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer

Not yet recruiting
2
29
US
Radiation Therapy, Cancer Radiotherapy, Energy Type, Irradiate, Irradiated, irradiation, Radiation, Radiation Therapy, Therapy, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Pembrolizumab, 1374853-91-4, BCD-201, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized, Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, Pembrolizumab, Biosimilar BCD-201, SCH 900475, Nab-paclitaxel, ABI 007, ABI-007, ABI-007, Abraxane, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound, Paclitaxel, nanoparticle paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel nanoparticle albumin-bound,, Paclitaxel Protein-Bound, protein-bound paclitaxel, Protein-bound Paclitaxel, Paclitaxel, 33069-62-4,5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one,4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine, [2aR-[2a Alpha,4beta,4a beta,6beta, Carboplatin, SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum, 1,1-cyclobutanedicarboxylic acid platinum complex, 41575-94-4, Blastocarb, Carboplat, CARBOPLATIN,, Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II),, complex, 41575-94-4, Blastocarb, Carboplat, CARBOPLATIN, Carboplatin, Carboplatin Hexal, Carboplatino, Carboplatinum,, Carbosin, Carbosol, Carbotec, CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum,, Gemcitabine, 1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, 2'Deoxy-2',2'-Difluorocytidine, 95058-81-4, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine, GEMCITABINE,, Biopsy, Biopsy, BIOPSY_TYPE, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computed Tomography, Computerized Axial Tomography,Computerized Axial Tomography,, Bone Scan, Bone Scan, bone scan, Bone Scan, Bone Scan, Bone Scan, Bone Scintigraphy, Biospecimen Collection, Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection, Medical Chart Review, Chart Review, Medical Chart Review
Emory University, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC V8, Metastatic Triple-Negative Breast Carcinoma
02/25
02/26
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
NCT06460298: ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
1/2
51
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, ProAgio Dose Expansion
ProDa BioTech, LLC, Emory University, Georgia State University
Triple Negative Breast Cancer
07/26
10/26
NCT03769155: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Active, not recruiting
1
41
US
Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, VX15/2503, moAb VX15/2503, Pepinemab, Surgery
Emory University, Bristol-Myers Squibb, Vaccinex Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
12/23
12/32
NCT05304962: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Recruiting
1
64
US
RGT-419B, RGT-419B in combination with hormonal therapy
Regor Pharmaceuticals Inc.
Breast Cancer
12/25
09/26
NCT05464810: Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting
1
40
US
Letrozole, CGS 20267, Femara, Simvastatin, MK 733, Synvinolin, Zocor
Emory University, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma
04/25
04/25
NCT05488145: A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Recruiting
N/A
30
US
Best Practice, Internet-Based Intervention, Questionnaire Administration, Survey Administration
Emory University, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
02/26
06/26
NCI-2022-01726, NCT05368428: Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Recruiting
N/A
27
US
Transcutaneous Electrical Nerve Stimulation, TENS, transcutaneous electric nerve stimulation
Emory University, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Early Stage Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/25
03/25
NCT05877859: Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Recruiting
N/A
10
US
Emory University, National Cancer Institute (NCI)
Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
04/25
04/26
NCT06534125: Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women with Early-Stage Breast Cancer

Recruiting
N/A
150
US
Acupressure Therapy, Acupressure, Ischemic Compression, Acupuncture Therapy, Acupuncture, Aromatase Inhibition Therapy, Aromatase Inhibition, Discussion, Discuss, Survey Administration
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
12/25
12/26
Hayduchok, Christina
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
Haydouck, Christina
No trials found

Download Options